Literature DB >> 24157367

Cytidine derivatives as IspF inhibitors of Burkolderia pseudomallei.

Zheng Zhang1, Sriram Jakkaraju, Joy Blain, Kenneth Gogol, Lei Zhao, Robert C Hartley, Courtney A Karlsson, Bart L Staker, Thomas E Edwards, Lance J Stewart, Peter J Myler, Michael Clare, Darren W Begley, James R Horn, Timothy J Hagen.   

Abstract

Published biological data suggest that the methyl erythritol phosphate (MEP) pathway, a non-mevalonate isoprenoid biosynthetic pathway, is essential for certain bacteria and other infectious disease organisms. One highly conserved enzyme in the MEP pathway is 2C-methyl-d-erythritol 2,4-cyclodiphosphate synthase (IspF). Fragment-bound complexes of IspF from Burkholderia pseudomallei were used to design and synthesize a series of molecules linking the cytidine moiety to different zinc pocket fragment binders. Testing by surface plasmon resonance (SPR) found one molecule in the series to possess binding affinity equal to that of cytidine diphosphate, despite lacking any metal-coordinating phosphate groups. Close inspection of the SPR data suggest different binding stoichiometries between IspF and test compounds. Crystallographic analysis shows important variations between the binding mode of one synthesized compound and the pose of the bound fragment from which it was designed. The binding modes of these molecules add to our structural knowledge base for IspF and suggest future refinements in this compound series.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-infective; Fragment screening; IspF; MEP pathway; Non-mevalonate; SPR

Mesh:

Substances:

Year:  2013        PMID: 24157367      PMCID: PMC3874807          DOI: 10.1016/j.bmcl.2013.09.101

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

Review 1.  Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.

Authors:  E E Slater; J S MacDonald
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Structure of 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids.

Authors:  Stefan Steinbacher; Johannes Kaiser; Juraithip Wungsintaweekul; Stefan Hecht; Wolfgang Eisenreich; Stefan Gerhardt; Adelbert Bacher; Felix Rohdich
Journal:  J Mol Biol       Date:  2002-02-08       Impact factor: 5.469

3.  Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate.

Authors:  M Rohmer; M Knani; P Simonin; B Sutter; H Sahm
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

4.  Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei.

Authors:  Darren W Begley; Robert C Hartley; Douglas R Davies; Thomas E Edwards; Jess T Leonard; Jan Abendroth; Courtney A Burris; Janhavi Bhandari; Peter J Myler; Bart L Staker; Lance J Stewart
Journal:  J Struct Funct Genomics       Date:  2011-02-26

Review 5.  Biosynthesis of isoprenoids via the non-mevalonate pathway.

Authors:  W Eisenreich; A Bacher; D Arigoni; F Rohdich
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

6.  Fosmidomycin for malaria.

Authors:  Michel A Missinou; Steffen Borrmann; Andreas Schindler; Saadou Issifou; Ayola A Adegnika; Pierre-Blaise Matsiegui; Ronald Binder; Bertrand Lell; Jochen Wiesner; Thomas Baranek; Hassan Jomaa; Peter G Kremsner
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

7.  In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin.

Authors:  Jochen Wiesner; Dajana Henschker; David B Hutchinson; Ewald Beck; Hassan Jomaa
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

8.  Discovery of Inhibitors of Burkholderia pseudomallei Methionine Aminopeptidase with Antibacterial Activity.

Authors:  Phumvadee Wangtrakuldee; Matthew S Byrd; Cristine G Campos; Michael W Henderson; Zheng Zhang; Michael Clare; Ali Masoudi; Peter J Myler; James R Horn; Peggy A Cotter; Timothy J Hagen
Journal:  ACS Med Chem Lett       Date:  2013-07-01       Impact factor: 4.345

9.  Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.

Authors:  Douglas R Davies; Bjorn Mamat; Olafur T Magnusson; Jeff Christensen; Magnus H Haraldsson; Rama Mishra; Brian Pease; Erik Hansen; Jasbir Singh; David Zembower; Hidong Kim; Alex S Kiselyov; Alex B Burgin; Mark E Gurney; Lance J Stewart
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

10.  Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.

Authors:  Ronnatrai Ruangweerayut; Sornchai Looareesuwan; David Hutchinson; Anurak Chauemung; Vick Banmairuroi; Kesara Na-Bangchang
Journal:  Malar J       Date:  2008-10-31       Impact factor: 2.979

View more
  3 in total

1.  MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.

Authors:  Xu Wang; Rachel L Edwards; Haley Ball; Claire Johnson; Amanda Haymond; Misgina Girma; Michelle Manikkam; Robert C Brothers; Kyle T McKay; Stacy D Arnett; Damon M Osbourn; Sophie Alvarez; Helena I Boshoff; Marvin J Meyers; Robin D Couch; Audrey R Odom John; Cynthia S Dowd
Journal:  J Med Chem       Date:  2018-09-24       Impact factor: 7.446

2.  (Z)-4-Chloro-N-{3-[(4-chlorophenyl)sulfonyl]-2,3-dihydrobenzo[d]thiazol-2-ylidene}benzene-sulfonamide.

Authors:  Sydney M Watkins; Timothy J Hagen; Timothy S Perkins; Chong Zheng
Journal:  IUCrdata       Date:  2017-06-20

3.  Kinetic characterization and allosteric inhibition of the Yersinia pestis 1-deoxy-D-xylulose 5-phosphate reductoisomerase (MEP synthase).

Authors:  Amanda Haymond; Chinchu Johny; Tyrone Dowdy; Brandon Schweibenz; Karen Villarroel; Richard Young; Clark J Mantooth; Trishal Patel; Jessica Bases; Geraldine San Jose; Emily R Jackson; Cynthia S Dowd; Robin D Couch
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.